ClinicalTrials.gg
TerminatedNCT03354637Updated Jun 5, 2020Results posted

A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

A Phase 2 interventional study of ATI-50002 high dose and ATI-50002 low dose in Alopecia Areata, sponsored by Aclaris Therapeutics, Inc.. Terminated at 23 sites in United States. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2020-06-05.

Sponsored by Aclaris Therapeutics, Inc. · Phase 2, Interventional, and Treatment

Why this study was terminated
The double-blind primary endpoint was not met. Open Label Extension period halted as a result.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
129
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 98 studies in Alopecia Areata with a site in United States — 21 open to participants now, 32 under way, 8 of them phase 3. Alopecia Areata · United States.

Enrollment
20th of 84
129 · median 46
Started
2017
with 2 others
Phase 2
42 of 98
8 open now
Registered
34th of 98
by date
Lead sponsor
3 of 98
Aclaris Therapeutics, Inc.

Among the 98 studies in Alopecia Areata with a site in United States, this one is the 20th largest by enrollment of the 84 interventional ones that give a count, is one of 3 that started in 2017, is one of 42 in phase 2, and was the 34th registered.

Alopecia Areata

221 studies on the registry are indexed under Alopecia Areata; 62 are open to participants now.

Browse Alopecia Areata studies →

Open to participants now

21 of the 98 studies in Alopecia Areata with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 42 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 21 (50%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Alopecia Areata with a site in United States, or all of them as a file.
02

Study summary

Primary:

  • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA)

Secondary:

  • To evaluate key clinical outcome assessments
Read the detailed description

Primary:

  • To assess safety, tolerability and efficacy of 2 dose strengths of ATI-50002 Topical Solution, compared to vehicle in subjects with alopecia areata (AA)

Secondary:

  • To evaluate key clinical outcome assessments
03

Conditions studied

  • Alopecia Areata

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of stable patchy alopecia areata (AA) defined as no current areas of spontaneous regrowth.
  2. Have a Severity of Alopecia Tool (SALT) score of at least 15% up to 95% total scalp hair loss determined by the study investigator at baseline.
  3. Have a duration of the current episode of scalp hair loss of a minimum of 6 months and a maximum of 12 years.
  4. If a woman of (WOCBP), must have a negative serum pregnancy test at Screening (Visit 1) and a negative urine pregnancy test at Baseline (Visit 2) and agree to: use a highly effective method of for the duration of the study; not be planning a pregnancy during the study duration and use contraception for 30 days after last application of study medication.

Exclusion criteria

Exclusion Criteria:

  1. Females who are nursing, pregnant, or planning to become pregnant for the duration of the study and up to 30 days after the last application of study medication.
  2. Diffuse alopecia areata.
  3. Concomitant hair loss disorder (by history or physical exam) such as androgenetic alopecia or scarring alopecia (e.g., cicatricial alopecia, frontal fibrosing alopecia, etc.).
  4. Active skin disease on the scalp (such as psoriasis or seborrheic dermatitis) or a history of skin disease on the scalp that in the opinion of the investigator would interfere with the study assessments of efficacy or safety.
  5. Active scalp trauma or other condition affecting the scalp that, in the investigator's opinion, may affect the course of AA or interfere with the study conduct or evaluations.
  6. The presence of a permanent or difficult to remove hairpiece or wig that will, in the opinion of the investigator, interfere with study assessments if not removed at each visit.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
129 participants (actual)

Study arms

  • Active comparator
    ATI-50002 high dose Topical Solution

    High dose active

    Drug: ATI-50002 high dose

  • Active comparator
    ATI-50002 low dose Topical Solution

    low dose active

    Drug: ATI-50002 low dose

  • Placebo comparator
    Vehicle Topical Solution

    placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in the Severity of Alopecia Tool Score at Week 24

    The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth. The primary efficacy variable was the percent change from baseline in SALT score at Week 24. This was calculated as the mean of the changes from Baseline (Visit 2) SALT score to Week 24 (Visit 10) SALT score, divided by Baseline SALT score and expressed as a percentage.

    Time frame: Baseline - Week 24

Secondary outcomes

  1. Percent Change From Baseline in the Alopecia Density and Extent Score at Week 24

    The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.

    Time frame: Baseline - Week 24

  2. Mean Change From Baseline in Severity of Alopecia Tool Score at Week 24

    The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth.

    Time frame: Baseline - Week 24

  3. Mean Change From Baseline in Alopecia Density and Extent Score at Week 24

    The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.

    Time frame: Baseline - Week 24

  4. Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Severity of Alopecia Tool Scores at Week 24

    A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Severity of Alopecia Tool scores at Week 24 is presented.

    Time frame: Baseline - Week 24

  5. Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Alopecia Density and Extent Scores at Week 24

    A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Alopecia Density and Extent scores at Week 24 is presented.

    Time frame: Baseline - Week 24

  6. Proportion of Subjects With ≥2 Point Improvement in Scalp Patient Reported Outcome for Target Patch at Week 24

    The Scalp Patient Reported Outcome for Target Patch assesses the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Subject Target Patch assessment at Week 24 compared to baseline is presented.

    Time frame: Baseline - Week 24

  7. Proportion of Subjects With ≥1 Point Improvement in Scalp Patient Reported Outcome for Entire Scalp at Week 24

    The Scalp Patient Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥1 point improvement in Subject Entire Scalp assessment at Week 24 compared to baseline is presented.

    Time frame: Baseline - Week 24

  8. Proportion of Subjects With ≥2-Point Improvement in Scalp Clinician Reported Outcome for Target Patch at Week 24

    The Scalp Clinician Reported Outcome for Target Patch provides the investigator's assessment of the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Clinician Target Patch assessment at Week 24 compared to baseline is presented.

    Time frame: Baseline - Week 24

  9. Change From Baseline in Scalp Clinician Reported Outcome for Entire Scalp at Week 24

    The Scalp Clinician Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.

    Time frame: Baseline - Week 24

  10. Change From Baseline in the Physician Global Impression of Severity (PhGIS) of Patchy Alopecia Areata at Week 24

    The Physician Global Impression of Severity (PhGIS) is a 5-point descriptive scale completed by investigators at Baseline, Week 4, Week 12, and Week 24 and is used to capture the investigator's assessment of the subject's disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.

    Time frame: Baseline - Week 24

  11. Change From Baseline in the Subject Global Impression of Severity of Patchy Alopecia Areata at Week 24

    The Subject Global Impression of Severity (SGIS) is a 5-point descriptive scale completed by subjects at Baseline, Week 4, Week 12, and Week 24 and is used to capture the subject's assessment of disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.

    Time frame: Baseline - Week 24

  12. Alopecia Impact Assessment Patient Reported Outcome Change From Baseline at Week 24

    The Alopecia Impact Assessment (AIA) is a 13-item patient reported outcome questionnaire which measures the subject's experience with impacts related to alopecia areata in managing appearance, worry, sadness, loss of confidence, self-consciousness, embarrassment, feeling unattractive, limitation of social activities, limitation of physical activities, unwanted attention, sweat in eyes, debris in eyes, and debris in nose. The AIA was completed by subjects at Baseline, Week 4, Week 12, and Week 24 and has a recall period of "over the past seven days". An 11-point NRS with anchors "0 - Not at all \[impact\]" and "10 - Extremely \[impact\]" (e.g., "Not at all bothersome" and "Extremely bothersome"; "Not at all worried" and "Extremely worried") is utilized. The AIA produces single-item (0-10) and mean total (0-10) scores, with higher scores indicating higher levels of impact.

    Time frame: Baseline - Week 24

  13. Subject Global Impression of Treatment Satisfaction at Week 24

    The Subject Global Impression of Treatment Satisfaction (SGITS) is a 7-point descriptive scale completed by subjects at Week 12 and Week 24. Scale response options ranged from "1. Extremely Satisfied" to "7. Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied they are with the study medication treatment received for their alopecia areata.

    Time frame: Week 24

  14. Change in Dermatology Life Quality Index Total Score Between Baseline and Week 24

    The 10 question Dermatology Life Quality Index (DLQI) questionnaire was completed by subjects at Baseline, Week 4, Week 12, and Week 24. When completing the questionnaire, subjects were instructed to think of their hair loss in place of "skin problem" and "skin" as referenced in the questionnaire. Possible summary scores could range from 0 to 30 with higher scores indicating a worse outcome.

    Time frame: Baseline - Week 24

  15. Physician Global Impression of Change at Week 24

    The Physician Global Impression of Change (PhGIC) is a 7-point descriptive scale completed by investigators at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the investigator's overall impression of change for the subject's alopecia during the treatment period.

    Time frame: Week 24

  16. Subject Global Impression of Change at Week 24

    The Subject Global Impression of Change (SGIC) is a 7-point descriptive scale completed by subjects at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the subject's overall impression of change for his/her alopecia during the treatment period.

    Time frame: Week 24

07

Results

Posted Jun 5, 2020

Participant flow

Double-blind Period
Participant flow — Double-blind Period
MilestoneVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Started434442
Completed263135
Not completed17137
Withdrew: Protocol violation200
Withdrew: Adverse event120
Withdrew: Lost to follow-up343
Withdrew: Withdrawal by subject1064
Withdrew: Incomplete efficacy data collection110
Open Label Extension
Participant flow — Open Label Extension
MilestoneVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Started0061
Completed0033
Not completed0028
Withdrew: Adverse event001
Withdrew: Lost to follow-up002
Withdrew: Withdrawal by subject005
Withdrew: Study terminated by sponsor0017
Withdrew: Subject noncompliance001
Withdrew: Lack of efficacy001
Withdrew: Physician decision001

Outcome measures

PrimaryPercent Change From Baseline in the Severity of Alopecia Tool Score at Week 24

The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth. The primary efficacy variable was the percent change from baseline in SALT score at Week 24. This was calculated as the mean of the changes from Baseline (Visit 2) SALT score to Week 24 (Visit 10) SALT score, divided by Baseline SALT score and expressed as a percentage.

Time frame:
Baseline - Week 24
Reported as:
Least squares mean · score on a scale
Percent Change From Baseline in the Severity of Alopecia Tool Score at Week 24
score on a scaleVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Percent Change From Baseline in the Severity of Alopecia Tool Score at Week 24-18.54 ± 4.705-4.66 ± 4.707-9.22 ± 4.784
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.038 (All statistical testing was two-sided and performed using a significance (alpha) level of 0.05.) · Mean difference (final values): 13.88 · 95% CI 0.77 to 27.00
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.166 (All statistical testing was two-sided and performed using a significance (alpha) level of 0.05.) · Mean difference (final values): 9.32 · 95% CI -3.90 to 22.55
SecondaryPercent Change From Baseline in the Alopecia Density and Extent Score at Week 24

The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.

Time frame:
Baseline - Week 24
Reported as:
Least squares mean · score on a scale
Percent Change From Baseline in the Alopecia Density and Extent Score at Week 24
score on a scaleVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Percent Change From Baseline in the Alopecia Density and Extent Score at Week 24-14.75 ± 4.508-8.15 ± 4.511-11.52 ± 4.584
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.302 · Mean difference (final values): 6.60 · 95% CI -5.97 to 19.17
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.616 · Mean difference (final values): 3.23 · 95% CI -9.44 to 15.90
SecondaryMean Change From Baseline in Severity of Alopecia Tool Score at Week 24

The Severity of Alopecia Tool (SALT) score is a physician administered scale measuring the amount of scalp without any terminal hair. Possible scores range from 0 (no scalp hair loss) to 100 (complete scalp hair loss). A negative change in the SALT score over time represents hair regrowth.

Time frame:
Baseline - Week 24
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Severity of Alopecia Tool Score at Week 24
score on a scaleVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Mean Change From Baseline in Severity of Alopecia Tool Score at Week 24-6.47 ± 2.071-1.95 ± 2.074-2.94 ± 2.107
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.125 · Mean difference (final values): 4.52 · 95% CI -1.26 to 10.30
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.234 · Mean difference (final values): 3.53 · 95% CI -2.30 to 9.36
SecondaryMean Change From Baseline in Alopecia Density and Extent Score at Week 24

The Alopecia Density and Extent (ALODEX) score is a measurement of the amount of scalp with terminal hair loss assessed by the investigator at Baseline, Week 4, Week 8, Week 12, Week 16, Week 20, and Week 24. ALODEX breaks the scalp up into a grid of 1% scalp surface areas and assigns density rating in each area on a 10 point scale of hair loss (0= no hair loss to 10 = complete baldness). Summation of scores from each 1% scalp surface area provides an overall score which may range from 0 (no scalp hair loss) to 100 (complete baldness). A negative change in the ALODEX score over time represents hair regrowth.

Time frame:
Baseline - Week 24
Reported as:
Least squares mean · score on a scale
Mean Change From Baseline in Alopecia Density and Extent Score at Week 24
score on a scaleVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Mean Change From Baseline in Alopecia Density and Extent Score at Week 24-4.91 ± 2.129-3.36 ± 2.131-4.98 ± 2.165
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.607 · Mean difference (final values): 1.55 · 95% CI -4.39 to 7.49
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.981 · Mean difference (final values): -0.07 · 95% CI -6.06 to 5.92
SecondaryProportion of Subjects Achieving ≥50% Hair Regrowth Based on Severity of Alopecia Tool Scores at Week 24

A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Severity of Alopecia Tool scores at Week 24 is presented.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Severity of Alopecia Tool Scores at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Severity of Alopecia Tool Scores at Week 24578
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.620 · Odds ratio (or): 1.4 · 95% CI 0.4 to 4.6
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.366 · Odds ratio (or): 1.7 · 95% CI 0.5 to 5.8
SecondaryProportion of Subjects Achieving ≥50% Hair Regrowth Based on Alopecia Density and Extent Scores at Week 24

A summary of the proportion of subjects in each treatment arm achieving ≥50% hair regrowth compared with baseline using Alopecia Density and Extent scores at Week 24 is presented.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Alopecia Density and Extent Scores at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Proportion of Subjects Achieving ≥50% Hair Regrowth Based on Alopecia Density and Extent Scores at Week 24688
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.157 · Odds ratio (or): 0.1 · 95% CI 0.0 to 2.3
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.353 · Odds ratio (or): 0.4 · 95% CI 0.1 to 2.8
SecondaryProportion of Subjects With ≥2 Point Improvement in Scalp Patient Reported Outcome for Target Patch at Week 24

The Scalp Patient Reported Outcome for Target Patch assesses the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Subject Target Patch assessment at Week 24 compared to baseline is presented.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Proportion of Subjects With ≥2 Point Improvement in Scalp Patient Reported Outcome for Target Patch at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Proportion of Subjects With ≥2 Point Improvement in Scalp Patient Reported Outcome for Target Patch at Week 24689
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.333 · Odds ratio (or): 1.7 · 95% CI 0.6 to 5.4
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.388 · Odds ratio (or): 1.7 · 95% CI 0.5 to 5.2
SecondaryProportion of Subjects With ≥1 Point Improvement in Scalp Patient Reported Outcome for Entire Scalp at Week 24

The Scalp Patient Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by subjects at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥1 point improvement in Subject Entire Scalp assessment at Week 24 compared to baseline is presented.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Proportion of Subjects With ≥1 Point Improvement in Scalp Patient Reported Outcome for Entire Scalp at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Proportion of Subjects With ≥1 Point Improvement in Scalp Patient Reported Outcome for Entire Scalp at Week 2413109
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.435 · Odds ratio (or): 0.7 · 95% CI 0.3 to 1.8
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.370 · Odds ratio (or): 0.6 · 95% CI 0.2 to 1.7
SecondaryProportion of Subjects With ≥2-Point Improvement in Scalp Clinician Reported Outcome for Target Patch at Week 24

The Scalp Clinician Reported Outcome for Target Patch provides the investigator's assessment of the appearance of the subject's target patch (identified by the subject as his or her most bothersome area of scalp hair loss at Baseline) and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, scalp of the target patch completely covered with hair" to "no hair, scalp of the target patch completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. A summary of the proportion of subjects with ≥2 point improvement in Clinician Target Patch assessment at Week 24 compared to baseline is presented.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Proportion of Subjects With ≥2-Point Improvement in Scalp Clinician Reported Outcome for Target Patch at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Proportion of Subjects With ≥2-Point Improvement in Scalp Clinician Reported Outcome for Target Patch at Week 246109
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Mixed Models Analysis · p = 0.333 · Odds ratio (or): 1.7 · 95% CI 0.6 to 5.4
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Mixed Models Analysis · p = 0.388 · Odds ratio (or): 1.7 · 95% CI 0.5 to 5.2
SecondaryChange From Baseline in Scalp Clinician Reported Outcome for Entire Scalp at Week 24

The Scalp Clinician Reported Outcome for Entire Scalp assesses the appearance of the subject's whole scalp and was completed by investigators at Baseline, Week 4, Week 12, and Week 24. The assessment has a recall period of "right now" and includes a five-point VRS ranging from "Full hair, whole scalp completely covered with hair" to "no hair, whole scalp completely exposed." The instrument produces a score of 1 to 5, with lower scores indicating more hair covering the subject's target patch. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Change From Baseline in Scalp Clinician Reported Outcome for Entire Scalp at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Better by 4 points000
Better by 3 points001
Better by 2 points122
Better by 1 points1198
No change272723
Worse by 1 point457
Worse by 2 point011
Worse by 3 point000
Worse by 4 point000
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.505
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.359
SecondaryChange From Baseline in the Physician Global Impression of Severity (PhGIS) of Patchy Alopecia Areata at Week 24

The Physician Global Impression of Severity (PhGIS) is a 5-point descriptive scale completed by investigators at Baseline, Week 4, Week 12, and Week 24 and is used to capture the investigator's assessment of the subject's disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Change From Baseline in the Physician Global Impression of Severity (PhGIS) of Patchy Alopecia Areata at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Better by 4 points000
Better by 3 points000
Better by 2 points544
Better by 1 point91012
No change272619
Worse by 1 point135
Worse by 2 points111
Worse by 3 points001
Worse by 4 points000
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.602
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.643
SecondaryChange From Baseline in the Subject Global Impression of Severity of Patchy Alopecia Areata at Week 24

The Subject Global Impression of Severity (SGIS) is a 5-point descriptive scale completed by subjects at Baseline, Week 4, Week 12, and Week 24 and is used to capture the subject's assessment of disease severity at a particular timepoint. Scores of 1 to 5 are assigned to responses Mild to Extremely Severe, respectively. Change status is categorized as 'Better by x points' when the score decreases from baseline by x points, and as 'Worse by x points' when the score increases by x points.

Time frame:
Baseline - Week 24
Reported as:
Count of participants · Participants
Change From Baseline in the Subject Global Impression of Severity of Patchy Alopecia Areata at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Better by 4 points010
Better by 3 points123
Better by 2 points655
Better by 1 point949
No change112017
Worse by 1 point1487
Worse by 2 points241
Worse by 3 points000
Worse by 4 points000
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.992
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.257
SecondaryAlopecia Impact Assessment Patient Reported Outcome Change From Baseline at Week 24

The Alopecia Impact Assessment (AIA) is a 13-item patient reported outcome questionnaire which measures the subject's experience with impacts related to alopecia areata in managing appearance, worry, sadness, loss of confidence, self-consciousness, embarrassment, feeling unattractive, limitation of social activities, limitation of physical activities, unwanted attention, sweat in eyes, debris in eyes, and debris in nose. The AIA was completed by subjects at Baseline, Week 4, Week 12, and Week 24 and has a recall period of "over the past seven days". An 11-point NRS with anchors "0 - Not at all \[impact\]" and "10 - Extremely \[impact\]" (e.g., "Not at all bothersome" and "Extremely bothersome"; "Not at all worried" and "Extremely worried") is utilized. The AIA produces single-item (0-10) and mean total (0-10) scores, with higher scores indicating higher levels of impact.

Time frame:
Baseline - Week 24
Reported as:
Mean · score on a scale
Alopecia Impact Assessment Patient Reported Outcome Change From Baseline at Week 24
score on a scaleVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Alopecia Impact Assessment Patient Reported Outcome Change From Baseline at Week 24-0.8 ± 2.21-0.8 ± 2.26-1.0 ± 2.30
SecondarySubject Global Impression of Treatment Satisfaction at Week 24

The Subject Global Impression of Treatment Satisfaction (SGITS) is a 7-point descriptive scale completed by subjects at Week 12 and Week 24. Scale response options ranged from "1. Extremely Satisfied" to "7. Extremely Dissatisfied" and are used to capture how satisfied or dissatisfied they are with the study medication treatment received for their alopecia areata.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Subject Global Impression of Treatment Satisfaction at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
1. Extremely satisfied589
2. Moderately satisfied657
3. A little satisfied573
4. Neither satisfied or dissatisfied586
5. A little dissatisfied342
6. Moderately dissatisfied534
7. Extremely dissatisfied967
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.374
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.253
SecondaryChange in Dermatology Life Quality Index Total Score Between Baseline and Week 24

The 10 question Dermatology Life Quality Index (DLQI) questionnaire was completed by subjects at Baseline, Week 4, Week 12, and Week 24. When completing the questionnaire, subjects were instructed to think of their hair loss in place of "skin problem" and "skin" as referenced in the questionnaire. Possible summary scores could range from 0 to 30 with higher scores indicating a worse outcome.

Time frame:
Baseline - Week 24
Reported as:
Mean · score on a scale
Change in Dermatology Life Quality Index Total Score Between Baseline and Week 24
score on a scaleVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
Change in Dermatology Life Quality Index Total Score Between Baseline and Week 24-0.5 ± 7.64-1.1 ± 4.07-2.2 ± 5.46
SecondaryPhysician Global Impression of Change at Week 24

The Physician Global Impression of Change (PhGIC) is a 7-point descriptive scale completed by investigators at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the investigator's overall impression of change for the subject's alopecia during the treatment period.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Physician Global Impression of Change at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
1. Very much improved216
2. Much improved332
3. A little improved1079
4. No change8128
5. A little worse044
6. Much worse111
7. Very much worse122
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.102
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.859
SecondarySubject Global Impression of Change at Week 24

The Subject Global Impression of Change (SGIC) is a 7-point descriptive scale completed by subjects at Week 24. Scale response options ranged from "1. Very much improved" to "7. Very much worse" and are used to capture the subject's overall impression of change for his/her alopecia during the treatment period.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Subject Global Impression of Change at Week 24
ParticipantsVehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical Solution
1. Very much improved413
2. Much improved246
3. A little improved8105
4. No change348
5. A little worse446
6. Much worse331
7. Very much worse114
Statistical analysis
  • Vehicle Topical Solution vs ATI-50002 0.12% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.481
  • Vehicle Topical Solution vs ATI-50002 0.46% Topical Solution · Wilcoxon (Mann-Whitney) · p = 0.357

Adverse events

Collected over Double blind period = 6 months; Open label extension period = 6 months; Reporting of non-serious AEs started with each subject's first study medication application and continued until the end of the subject's last study visit. Reporting for SAEs started when the subject signed the informed consent document and continued until the end of the subject's last visit.. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Topical Solution (Double Blind Period)0/43 (0%)0/43 (0%)21/43 (48.8%)
ATI-50002 0.12% Topical Solution (Double Blind Period)0/44 (0%)2/44 (4.5%)19/44 (43.2%)
ATI-50002 0.46% Topical Solution (Double Blind Period)0/42 (0%)0/42 (0%)14/42 (33.3%)
ATI-50002 0.46% Topical Solution (Open Label Extension Period)0/59 (0%)0/59 (0%)27/59 (45.8%)
Most frequent serious events
Most frequent serious events
EventVehicle Topical Solution (Double Blind Period)ATI-50002 0.12% Topical Solution (Double Blind Period)ATI-50002 0.46% Topical Solution (Double Blind Period)ATI-50002 0.46% Topical Solution (Open Label Extension Period)
Application site lacerationGeneral disorders0/431/440/420/59
Polyneuropathy idiopathic progressiveNervous system disorders0/431/440/420/59
Most frequent other events
Showing 10 of 22
Most frequent other events
EventVehicle Topical Solution (Double Blind Period)ATI-50002 0.12% Topical Solution (Double Blind Period)ATI-50002 0.46% Topical Solution (Double Blind Period)ATI-50002 0.46% Topical Solution (Open Label Extension Period)
Application site pruritisGeneral disorders3/431/444/422/59
Upper respiratory tract infectionInfections and infestations0/432/444/425/59
White blood cells urine positiveInvestigations3/431/440/420/59
DiarrhoeaGastrointestinal disorders2/433/440/422/59
Blood creatine phosphokinase increasedInvestigations0/430/440/424/59
InfluenzaInfections and infestations1/430/442/422/59
NasopharyngitisInfections and infestations2/432/441/421/59
Urinary tract infectionInfections and infestations2/430/441/420/59
Blood uric acid increasedInvestigations2/430/440/420/59
Lymphocyte count decreasedInvestigations2/430/440/420/59

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
<=18 years3025
Between 18 and 65 years364037113
>=65 years44311
Age, Continuous
Age, Continuous(years)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
Mean42.0 ± 16.5842.1 ± 13.9240.5 ± 14.9941.5 ± 15.09
Sex: Female, Male
Sex: Female, Male(Participants)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
Female15131846
Male28312483
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
Hispanic or Latino84719
Not Hispanic or Latino23262372
Unknown or Not Reported12141238
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
American Indian or Alaska Native0000
Asian0314
Native Hawaiian or Other Pacific Islander0000
Black or African American1110728
White32293192
More than one race0000
Unknown or Not Reported0235
Region of Enrollment
Region of Enrollment(participants)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
United States434343129
Fitzpatrick Skin Type
Fitzpatrick Skin Type(Participants)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
I - Always Burns2327
II - Burns Easily12161442
III - Burns Moderately139931
IV - Burns Minimally66820
V - Rarely Burns67619
VI - Never Burns43310
Duration of Current Episode of Alopecia Areata
Duration of Current Episode of Alopecia Areata(weeks)Vehicle Topical SolutionATI-50002 0.12% Topical SolutionATI-50002 0.46% Topical SolutionTotal
Mean127.8 ± 104.13160.7 ± 140.67156.3 ± 140.95148.3 ± 129.55

1 further baseline measures are reported on the registry.

08

Study locations

23 sites
  • Aclaris Investigator Site
    Encinitas, California 92024, United States
  • Aclaris Investigator Site
    Laguna Hills, California 92653, United States
  • Aclaris Investigator Site
    Redwood City, California 94063, United States
  • Aclaris Investigator Site
    Washington, District of Columbia 20037, United States
  • Aclaris Investigator Site
    Boynton Beach, Florida 33472, United States
  • Aclaris Investigator Site
    Miami, Florida 33136, United States
  • Aclaris Investigator Site
    Boston, Massachusetts 02115, United States
  • Aclaris Investigator Site
    Clinton Township, Michigan 48038, United States
  • Aclaris Investigator Site
    Warren, Michigan 48088, United States
  • Aclaris Investigator Site
    Fridley, Minnesota 55432, United States
  • Aclaris Investigator Site
    Minneapolis, Minnesota 55455, United States
  • Aclaris Investigator Site
    Omaha, Nebraska 68144, United States
  • Aclaris Investigator Site
    New York, New York 10155, United States
  • Aclaris Investigator Site
    Durham, North Carolina 27710, United States
  • Aclaris Investigator Site
    Winston-Salem, North Carolina 27104, United States
  • Aclaris Investigator Site
    Portland, Oregon 97210, United States
  • Aclaris Investigator Site
    Fort Washington, Pennsylvania 19034, United States
  • Aclaris Investigator Site
    Knoxville, Tennessee 37922, United States
  • Aclaris Investigator Site
    Nashville, Tennessee 37215, United States
  • Aclaris Investigator Site
    Austin, Texas 78745, United States
  • Aclaris Investigator Site
    Austin, Texas 78759, United States
  • Aclaris Investigator Site
    San Antonio, Texas 78229, United States
  • Aclaris Investigator Site
    San Antonio, Texas 78745, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2017 to primary completion in Apr 2019, 16 months.

Results were first posted in Jun 2020, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2017
First posted
Nov 28, 2017
StartActual
Nov 29, 2017
Primary completionActual
Apr 18, 2019
CompletionActual
Sep 10, 2019
Results first posted
Jun 5, 2020
Last update
Jun 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03354637
Responsible party
Sponsor
First posted
Nov 28, 2017
Start date
Nov 29, 2017
Primary completion
Apr 18, 2019
Completion
Sep 10, 2019
Results posted
Jun 5, 2020
Last update
Jun 5, 2020

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ifidancitinib

Start the discussion